SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

JERSEY CITY, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced several poster presentations highlighting details from interim analyses of data from its ongoing Phase 3 FURI and CARES studies investigating the potential of ibrexafungerp as a treatment for invasive candidiasis (IC) and candidemia, including infections caused by Candida auris (C. auris). The posters were presented at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held in Lisbon, Portugal April 23-26, 2022.

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp's Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases

JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants were sold at a public offering price of $3.00 per share and accompanying warrants, and the pre-funded warrants were sold at a public offering price of $2.999 per pre-funded warrant and accompanying warrants. The total gross offering proceeds to SCYNEXIS from this offering were $45.0 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants or warrants. All of the shares of common stock, pre-funded warrants and warrants were offered by SCYNEXIS.

SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SCYNEXIS Inc (NASDAQ: SCYX) has announced interim data from its ongoing Phase 3 FURI and CARES studies of ibrexafungerp in severe fungal infections. FURI study included fungal infections patients who are either intolerant to standard antifungal therapy or experience refractory.

Scynexis's Oral Ibrexafungerp Shows Potency Against Severe Fungal Infections

JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $3.00 per share and accompanying warrants, and the pre-funded warrants are being sold at a public offering price of $2.999 per pre-funded warrant and accompanying warrants. The gross offering proceeds to SCYNEXIS from this offering are expected to be approximately $45.0 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants or warrants. All of the shares of common stock, pre-funded warrants and warrants are being offered by SCYNEXIS.

SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced positive interim data from its ongoing Phase 3 FURI and CARES studies.

SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

SCYNEXIS Inc (NASDAQ: SCYX) shares are trading lower after the company announced a public offering of common stock. The size of the offering was not disclosed.

Why Scynexis Shares Are Falling During Thursday's After-Hours Session

JERSEY CITY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers. SCYNEXIS intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock and warrants offered in the public offering (including shares underlying the pre-funded warrants). All of the shares of common stock and warrants in the offering will be sold by SCYNEXIS. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

Data from studies evaluating ibrexafungerp in serious fungal infections will be presented Data from studies evaluating ibrexafungerp in serious fungal infections will be presented

SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal

Advanced first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for approximately 55 percent of commercially-insured U.S. patients Advanced first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for approximately 55 percent of commercially-insured U.S. patients

SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives

JERSEY CITY, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced participation in three women's health conferences in April.

SCYNEXIS to Participate in Upcoming April Women's Health Medical Conferences

SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q4 2021 Results - Earnings Call Transcript

Scynexis (SCYX) delivered earnings and revenue surprises of -47.89% and 53.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Reports Q4 Loss, Lags Revenue Estimates

JERSEY CITY, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the fourth quarter and full year ended on December 31, 2021.

SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, will announce fourth quarter and full year 2021 financial results and provide a business update on Tuesday, March 29, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on the same day.

SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update

JERSEY CITY, N.J., March 08, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it has been named to Fast Company's annual list of the top 50 World's Most Innovative Companies for 2022.

SCYNEXIS Named to Fast Company's 2022 Top 50 List of the World's Most Innovative Companies

We are initiating Scynexis with a target price of USD 23 per share. SCYX offers an extremely attractive set up with 600% upside and limited downside (10-15%) considering its near cash.

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

JERSEY CITY, N.J., March 02, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced its participation in three in-person medical conferences and one virtual investor panel in March. Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a live panel discussion on drug development in Women's Health. Event details can be found below:

SCYNEXIS to Participate in Upcoming Scientific Conferences and Events

JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present during two virtual investor conferences in January.

SCYNEXIS to Participate in Upcoming January Investor Conferences

JERSEY CITY, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported the exercise of warrants to purchase 3.37 million shares of SCYNEXIS common stock for which SCYNEXIS accepted a reduced exercise price. Gross proceeds to SCYNEXIS are approximately $21.1 million. The exercised warrants were issued as Series 1 warrants in the Company's December 2020 financing. The remaining outstanding Series 1 warrants expired unexercised on December 21, 2021.

SCYNEXIS Reports the Exercise of Warrants Totalling $21.1 Million

A novel first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for more than 45% of commercially insured patients in the U.S. A novel first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for more than 45% of commercially insured patients in the U.S.

BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients

JERSEY CITY, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to ibrexafungerp for the indication of invasive candidiasis (IC).

European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS' Innovative Antifungal Ibrexafungerp for the Indication of Invasive Candidiasis

JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported the exercise of warrants to purchase 1.2 million shares of SCYNEXIS common stock by Federated Hermes Kaufmann Small Cap Fund and Dafna Lifescience LP for which SCYNEXIS accepted a reduced exercise price. Proceeds to SCYNEXIS are approximately $7.9 million. The exercised warrants were issued in SCYNEXIS's December 2019 financing. The remaining warrants issued in the December 2019 financing covering approximately 3.2 million shares of common stock expired unexercised on December 2, 2021.

SCYNEXIS Reports the Exercise of Warrants Totalling $7.9 Million

JERSEY CITY, N.J., Dec. 01, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that BREXAFEMME® (ibrexafungerp tablets) has been named as a Popular Science 2021 “Best of What's New” award winner in the Health category.

BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What's New Award in the Health Category

JERSEY CITY, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its novel antifungal, ibrexafungerp, during a webcast on Monday, December 6, at 10 a.m. ET.

SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6

Burry's $1 million position in Scynexis led to a $40 million increase in the company's market cap to $170 million.

News for SCYNEXIS Stock (SCYX)